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Lung cancer, the leading cause of cancer deaths in males for decades, has recently become one of
commonest causes for women too. As women delay the start of their family, the co-existence of
cancer and pregnancy is increasingly observed. Nevertheless, lung cancer during pregnancy
remains a rather uncommon condition with less than 70 cases published in recent years.
Non-small cell lung carcinoma is the commonest type accounting for about 85% of all cases.
Overall survival rates are low. Chemotherapy and/or targeted treatment have been used with
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Placental metastasispoor outcomes. The disease has been also found to affect the products of conception with no
short- or long-term consequences for the neonate. This article is referring to a narrative review
of lung cancers diagnosed in pregnant women around the world.
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Cancer complicates 1 in 1000 pregnancies. In the last few dec-
ades there has been a change in the socioeconomic, profes-
sional and cultural status of women, especially in the western
world, that has shifted the age of women at first pregnancy
in the third decade of their lives. Malignancies such as breast
cancer, melanoma and lymphoma are likely to be diagnosed
during this period and hence they are the commonest to com-
plicate pregnancies [1–3].
Others, like lung cancer, usually present later in life, and
therefore seldom coincide with pregnancy [4]. Lung cancer is
the second most common cancer type in women but it is also
the most lethal. Non-small cell lung cancer (NSCLC) is the
most common histological type accounting for 80–85% of all
gestations lung cancer, 10–15% are small cell lung cancer
(SCLC) and fewer that 5% are carcinoids of the lungs [4]. It
is estimated that over 105,000 new cases will be diagnosed in
the USA with approximately 70,000 deaths in 2015. Smoking
is linked to approximately 90% of lung cancer cases, however
there are other well recognized causes such as radon, asbestos,
chromium, family history, and dietary factors. The disease
occurs in older people with a peak incidence after the age of
65 and only 2% of cases will affect people under the age of
45 [5].
The scope of this article is to provide a narrative review
from the available data on diagnosis, treatment and prognosis
of gestational lung cancer. In addition, special references are
made to the rare phenomenon of placenta and fetus invasion.
Table 1 Demographics.
Number of cases published 66
Median age (range) 36 years (17–45)
Gestational week at cancers diagnosis (range) 27.3 weeks (8–38)
Histopathology
Non-small cell lung cancer 5.4 (8%)
Small cell lung cancer 12 (18%)
Smoking history
Absent 18 (27%)
Present 23 (35%)
Unknown 25 (38%)
Disease stage
Early (I–II) 1 (1.5%)
Advanced (III–IV) 64 (97%)
Unknown 1 (1.5%)
Table 2 Treatment and outcome.
Treatment
During gestation 16 (24%)
Post-partum 34 (51.5%)
No treatment 9 (13.5%)
Unknown 7 (11%)
Chemotherapy 40 (60.5%)
Erlotinib/Gefitinib 3 (4.5%)
Crizotinib 2 (3%)
Radiotherapy 3 (4.5%)
Maternal outcome (from diagnosis)
Death 1 month post-partum 8 (12%)
Alive in 3–5 months 26 (39.5%)
Alive in 6–11 months 20 (30.5%)
Alive in 12 months or more 12 (18%)
Products of conception (outcome)
Abortion (induced/spontaneous) 6/1
Healthy baby 54 (82%)
Fetal metastases 3 (4.5%)
Placental metastases 11 (17%)
Unknown 1
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The authors searched the Medline and the International Can-
cer in Pregnancy registration study (CIP study; www.cancerin-
pregnancy.org registered with clinical/trials. Gov, number
NCT 00330447).
Demographic data
The first case of lung cancer during pregnancy appeared in
1953 [6]. In total, 66 pathologically confirmed lung cancers
have been reported.
Median age was 36 years old (17–45 years) while the med-
ian maternal gestational age was 27.3 months ranging from 8
to 38 weeks. Eighty-two percentage of the cases were NSCLC
and 18% SCLC. At presentation, 97% of patients were diag-
nosed in advanced clinical stages (stages III–IV) probably indi-
cating that gestational lung cancer follows an aggressive
course. Regarding tobacco history, this was present in 35%
of patients and absent in 27% and in the rest 38% of pregnant
mothers there are no available information [4,7–13] Table 1.
Therapeutic management and prognosis
Almost half of patients (51.4%) were treated postpartum and
the rest (24%) during pregnancy. Platinum-based chemother-
apy was administered in 40 patients (60.5%) and targeted
treatment with erlotinib or gefitinib (4 patients) and crizotinib
(2 patients). All patients treated with targeted drug were found
to be positive for EGFR or EML4-ALK mutations. Only three
patients were managed with palliative radiotherapy. No major
responses to systemic chemotherapy have been noticed, while
targeted treatment offered disease stability for a period of sev-
eral months. Nevertheless, not enough data are available to
support the use of targeted therapy in gestational cancers.
Maternal survival was dismal. Twelve percentage of treated
women died within one month during postpartum period and
70% had an overall survival of a few months. However, 12
patients diagnosed mainly with an early stage disease, experi-
enced longer survival.
Concerning newborns’ outcome, 82% of them were born
healthy. Metastatic invasion of the products of conception
(placenta and fetus) was observed in 14 cases, 11 on the pla-
centa and 3 of the fetuses [4,7–13] Table 2.Discussion
Lung cancer mortality in women is still increasing in European
countries. There is also adequate evidence that smoker women
exhibit a double risk in developing lung cancer as compared to
males [14,15]. From the available data in the literature, it
becomes obvious that less than 50% of gestational lung can-
cers carry a positive smoking history, indicating that tobacco
doesn’t account as the only etiological factor in these young
women. Possibly other carcinogenic mechanisms i.e. EGFR
or ALK activating mutations could also be implicated [13].
NSCLC of adenocarcinoma type was the most frequent his-
tology, accounting for 80% of pregnant women. More than
97% of the published cases are diagnosed with locally
advanced or metastatic disease.
Almost 50% of patients have been treated with systemic
treatment during the postpartum period of pregnancy.
Platinum-based regimens were the most commonly combina-
tions used. Response rates were reported to be poor and
maternal survival short. Overall survival was between 3 and
9 months, with 12% of patients to be dead within the first
month postpartum. However, survival was longer (12 months
or more) in patients with early disease [4,7].
The administration of systemic chemotherapy during the
first trimester of pregnancy should be avoided due to the harm-
ful or lethal effects on the fetus. However, certain chemother-
apeutic drugs or combinations can be safely given during the
second and third trimesters [16–18]. Tyrosine kinase inhibitors
are generally not recommended during pregnancy. To date,
there are six cases reported: two with erlotinib, one with gefi-
tinib, one with erlotinib followed by gefitinib and two with
crizotinib given either during an unrecognized pregnancy or
after delivery. No major responses or fetus abnormalities have
been observed [11–13].
Most of pregnant mothers with cancer are giving birth to
healthy babies, although newborn prematurity including com-
plications such as respiratory distress, seizures or ventricular
hemorrhage has been noticed [1,2]. In this review, 82% of
deliveries gave birth to normal newborns.
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pregnant women with cancer. However, certain tumors are
more commonly associated with involvement of products of
conception such as melanoma (30%), cancer of unknown pri-
mary (22.5%), hematological malignancies (15%) or breast
cancer (14%). Recently lung cancer has been recognized as
an additional tumor with high predilection to the products
of conception (13%) [19–21].
Conclusions
In conclusion, in this narrative review it is emphasized that
lung cancer during pregnancy is becoming an emerging issue.
Nowadays, oncologists and gynecologists should be informed
of this coexistence. They should be aware that gestational lung
cancer (a) is diagnosed in advanced stages having an aggressive
behavior, (b) chemotherapy offers poor results, (c) overall sur-
vival is short and (d) placenta and fetus are often involved by
transmitted cancer cells, requiring thorough examination of
the products of conception. A retrospective as well as a
prospective testing for EGFR and ALK activating mutations
is of paramount importance in order to properly treat preg-
nant mothers with lung cancer.
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